Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age

Takahiro Nishida, Hiromichi Sonoda, Yasuhisa Oishi, Yoshihisa Tanoue, Atsuhiro Nakashima, Yuichi Shiokawa, Ryuji Tominaga

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

Background: The long-term results of mitral valve replacement (MVR; n = 631) with a bileaflet mechanical prosthesis or a Carpentier-Edwards Perimount bioprosthesis were evaluated in Japanese patients of different age groups. Methods: A total of 507 bileaflet mechanical prostheses and 124 bioprostheses have been implanted since 1982 at our institution. Follow-up was completed for 6,598 patient-years in 98.4% of the cases. Results: Among the patients 70 years of age and older, the rate of freedom from valve-related death and valve-related morbidity at 10 years after surgery were significantly better in the bioprostheses group (93.3% ± 6.4% and 83.7% ± 8.7%, respectively; n = 35) than in the mechanical prostheses group (71.1% ± 8.0% and 60.9% ± 8.9%, respectively; n = 82), and neither structural valve deterioration (SVD) nor resulting re-MVR were observed for bioprostheses. In contrast, among the patients 64 years and younger, no significant differences were observed in long-term survival between the mechanical prostheses group (n = 347) and the bioprostheses group (n = 76), while significantly lower rates of freedom from SVD and re-MVR were observed in the bioprostheses group compared with those obtained in the mechanical prostheses group. As for the controversial intermediate-age group of 65 to 69 years, the general tendencies were similar to those observed in the group 64 years and younger. Conclusions: Based on our comparative evaluation, bioprostheses should be chosen for MVR in patients 70 years of age and older, whereas mechanical prostheses were better in the patients 64 years of age and younger. The use of bioprostheses in Japanese patients 65 to 69 years of age is not preferable for preventing SVD and subsequent re-MVR.

元の言語英語
ページ(範囲)1614-1620
ページ数7
ジャーナルAnnals of Thoracic Surgery
96
発行部数5
DOI
出版物ステータス出版済み - 11 1 2013

Fingerprint

Bioprosthesis
Mitral Valve
Prostheses and Implants
Age Groups
Morbidity
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

これを引用

Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age. / Nishida, Takahiro; Sonoda, Hiromichi; Oishi, Yasuhisa; Tanoue, Yoshihisa; Nakashima, Atsuhiro; Shiokawa, Yuichi; Tominaga, Ryuji.

:: Annals of Thoracic Surgery, 巻 96, 番号 5, 01.11.2013, p. 1614-1620.

研究成果: ジャーナルへの寄稿記事

Nishida, Takahiro ; Sonoda, Hiromichi ; Oishi, Yasuhisa ; Tanoue, Yoshihisa ; Nakashima, Atsuhiro ; Shiokawa, Yuichi ; Tominaga, Ryuji. / Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age. :: Annals of Thoracic Surgery. 2013 ; 巻 96, 番号 5. pp. 1614-1620.
@article{f8c236b811914dc48f8c0ed2dceb0fad,
title = "Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age",
abstract = "Background: The long-term results of mitral valve replacement (MVR; n = 631) with a bileaflet mechanical prosthesis or a Carpentier-Edwards Perimount bioprosthesis were evaluated in Japanese patients of different age groups. Methods: A total of 507 bileaflet mechanical prostheses and 124 bioprostheses have been implanted since 1982 at our institution. Follow-up was completed for 6,598 patient-years in 98.4{\%} of the cases. Results: Among the patients 70 years of age and older, the rate of freedom from valve-related death and valve-related morbidity at 10 years after surgery were significantly better in the bioprostheses group (93.3{\%} ± 6.4{\%} and 83.7{\%} ± 8.7{\%}, respectively; n = 35) than in the mechanical prostheses group (71.1{\%} ± 8.0{\%} and 60.9{\%} ± 8.9{\%}, respectively; n = 82), and neither structural valve deterioration (SVD) nor resulting re-MVR were observed for bioprostheses. In contrast, among the patients 64 years and younger, no significant differences were observed in long-term survival between the mechanical prostheses group (n = 347) and the bioprostheses group (n = 76), while significantly lower rates of freedom from SVD and re-MVR were observed in the bioprostheses group compared with those obtained in the mechanical prostheses group. As for the controversial intermediate-age group of 65 to 69 years, the general tendencies were similar to those observed in the group 64 years and younger. Conclusions: Based on our comparative evaluation, bioprostheses should be chosen for MVR in patients 70 years of age and older, whereas mechanical prostheses were better in the patients 64 years of age and younger. The use of bioprostheses in Japanese patients 65 to 69 years of age is not preferable for preventing SVD and subsequent re-MVR.",
author = "Takahiro Nishida and Hiromichi Sonoda and Yasuhisa Oishi and Yoshihisa Tanoue and Atsuhiro Nakashima and Yuichi Shiokawa and Ryuji Tominaga",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.athoracsur.2013.05.014",
language = "English",
volume = "96",
pages = "1614--1620",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Mechanical prosthesis is reasonable for mitral valve replacement in patients approximately 65 years of age

AU - Nishida, Takahiro

AU - Sonoda, Hiromichi

AU - Oishi, Yasuhisa

AU - Tanoue, Yoshihisa

AU - Nakashima, Atsuhiro

AU - Shiokawa, Yuichi

AU - Tominaga, Ryuji

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: The long-term results of mitral valve replacement (MVR; n = 631) with a bileaflet mechanical prosthesis or a Carpentier-Edwards Perimount bioprosthesis were evaluated in Japanese patients of different age groups. Methods: A total of 507 bileaflet mechanical prostheses and 124 bioprostheses have been implanted since 1982 at our institution. Follow-up was completed for 6,598 patient-years in 98.4% of the cases. Results: Among the patients 70 years of age and older, the rate of freedom from valve-related death and valve-related morbidity at 10 years after surgery were significantly better in the bioprostheses group (93.3% ± 6.4% and 83.7% ± 8.7%, respectively; n = 35) than in the mechanical prostheses group (71.1% ± 8.0% and 60.9% ± 8.9%, respectively; n = 82), and neither structural valve deterioration (SVD) nor resulting re-MVR were observed for bioprostheses. In contrast, among the patients 64 years and younger, no significant differences were observed in long-term survival between the mechanical prostheses group (n = 347) and the bioprostheses group (n = 76), while significantly lower rates of freedom from SVD and re-MVR were observed in the bioprostheses group compared with those obtained in the mechanical prostheses group. As for the controversial intermediate-age group of 65 to 69 years, the general tendencies were similar to those observed in the group 64 years and younger. Conclusions: Based on our comparative evaluation, bioprostheses should be chosen for MVR in patients 70 years of age and older, whereas mechanical prostheses were better in the patients 64 years of age and younger. The use of bioprostheses in Japanese patients 65 to 69 years of age is not preferable for preventing SVD and subsequent re-MVR.

AB - Background: The long-term results of mitral valve replacement (MVR; n = 631) with a bileaflet mechanical prosthesis or a Carpentier-Edwards Perimount bioprosthesis were evaluated in Japanese patients of different age groups. Methods: A total of 507 bileaflet mechanical prostheses and 124 bioprostheses have been implanted since 1982 at our institution. Follow-up was completed for 6,598 patient-years in 98.4% of the cases. Results: Among the patients 70 years of age and older, the rate of freedom from valve-related death and valve-related morbidity at 10 years after surgery were significantly better in the bioprostheses group (93.3% ± 6.4% and 83.7% ± 8.7%, respectively; n = 35) than in the mechanical prostheses group (71.1% ± 8.0% and 60.9% ± 8.9%, respectively; n = 82), and neither structural valve deterioration (SVD) nor resulting re-MVR were observed for bioprostheses. In contrast, among the patients 64 years and younger, no significant differences were observed in long-term survival between the mechanical prostheses group (n = 347) and the bioprostheses group (n = 76), while significantly lower rates of freedom from SVD and re-MVR were observed in the bioprostheses group compared with those obtained in the mechanical prostheses group. As for the controversial intermediate-age group of 65 to 69 years, the general tendencies were similar to those observed in the group 64 years and younger. Conclusions: Based on our comparative evaluation, bioprostheses should be chosen for MVR in patients 70 years of age and older, whereas mechanical prostheses were better in the patients 64 years of age and younger. The use of bioprostheses in Japanese patients 65 to 69 years of age is not preferable for preventing SVD and subsequent re-MVR.

UR - http://www.scopus.com/inward/record.url?scp=84887117852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887117852&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2013.05.014

DO - 10.1016/j.athoracsur.2013.05.014

M3 - Article

C2 - 23891407

AN - SCOPUS:84887117852

VL - 96

SP - 1614

EP - 1620

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -